Prevention of 2019 nCoV infection through development and clinical testing of a novel Virus Like Particle (VLP) vaccine to expose coronavirus proteins to the immune system. Testimonial: Matti Sällberg (Head of Department of Laboratory Medicine, Karolinska Institute, Stockholm).Story: Three KI-led coronavirus projects selected in EU funding round.The project will use DNA vaccine technology to develop a vaccine that can also be used as a therapy against the virus. Rapid therapy development through Open Coronavirus Vaccine Platform. The projects, which involve 151 teams from across Europe and beyond, have started working on improving preparedness and response to outbreaks, rapid diagnostic tests, new treatments and new vaccines.Īmong these, 2 projects, are receiving €5.7 million to develop safe and effective vaccines: OPENCORONA In January 2020, the Commission launched an emergency call, through which €48.2 million were awarded to 18 research projects. It will work in close collaboration with the European Medicines Agency (EMA) to enable clinical trials for COVID-19 vaccines and prepare Europe for other emerging infectious diseases in the future. The European Corona Vaccine Trial Accelerator Platform (VACCELERATE) received a €12 million grant in February 2021 for the establishment of a clinical research network already spanning 21 countries. Vaccines and the fight against coronavirus New projects VACCELERATE United in developing a coronavirus vaccine Learn more about vaccines and the Commission’s vaccine strategy. Potential vaccines must receive the appropriate authorisations before they are allowed to be used in the general population. Regardless of the technology used, all new vaccines in the EU must go through strict controls and trials for their safety, as well as efficacy. Vaccines are developed using different approaches or technologies. The goal of a vaccine is to trigger an immune response, without causing the actual disease, that will subsequently provide some protection against an infection. In addition to the research spending, the Commission is investing €2.9 billion in the development of production capacities on the basis of the Advance Purchase Agreements. And one should also take into account the prices paid by Member States to purchase the vaccines, which brings the total amount of support to over €30 billion. It is important to make a distinction between funding for research and development of vaccines, investment in the development of production capacities, and the payment of the prices of the vaccines. Overall, the EU spent more than €1 billion in vaccine research from Horizon 2020. Prior to the dedicated COVID-19 investments, over €650 million had been invested through Horizon 2020 (2014-2020) in vaccine and vaccination research and innovation, also building on efforts from previous research and innovation programmes. €1 billion comes from H2020 (see breakdown), of which €350 million are dedicated to support coronavirus vaccine development. For the fight against COVID, the Commission pledged €1.4 billion under the global response.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |